Browsing: Stock

Coca-Cola (KO) stock jumped 5% on Tuesday after the company beat Wall Street’s earnings expectations and raised its guidance as consumers turned to lower-calorie trademark Coke options, such as Coke Zero and Diet Coke

Shares of Eton Pharmaceuticals Inc (ETON) jumped 10% on Tuesday, buoyed by Craig-Hallum’s optimism on the company’s pipeline and a fresh price target implying a potential upside of as much as 47% from its last close

Coca-Cola (KO) stock jumped 6% on Tuesday after the company beat Wall Street’s earnings expectations and raised its guidance as consumers turned to lower-calorie trademark Coke options, such as Coke Zero and Diet Coke

Edible Garden AG Incorporated stocks have been trading up by 72.93 percent following news of significant operational expansion and growth prospects

Edible Garden AG Incorporated stocks have been trading up by 154.14 percent amid heightened investor optimism from the most impactful news

Equity LifeStyle Properties (ELS) has just posted Q2 2026 results with total revenue of US$398.5 million and basic EPS of US$0.50, alongside funds from operations of US$154.5 million and FFO per share of US$0.77, set against trailing 12 month revenue of about US$1.6 billion and basic EPS of roughly US$2.08. Over recent quarters, revenue has…

The race to treat obesity and diabetes is shifting again after Eli Lilly pushed back approval plans for its next-generation obesity drug, retatrutide, to Q1 2027, even as phase 3 data showed weight loss of up to 22.6% and blood sugar benefits. This mix of regulatory delay and clinical progress can reshape expectations for companies…

Amgen stock sits at the intersection of mature biologic franchises and a broad late-stage pipeline that is increasingly focused on oncology and cardiometabolic diseases. The California-based biotechnology group Amgen Inc. (ISIN US0311621009) combines steady cash generation from legacy drugs such as Enbrel and Prolia with new assets in cancer and obesity, giving investors a blend…

Novo Nordisk stock is trading close to recent record levels, reflecting sustained investor confidence in the Danish pharmaceutical group (ISIN DK0062498333) as demand for its obesity and diabetes drugs continues to reshape earnings and market expectations

Novo Nordisk A/S (ISIN DK0062498333) stock is trading close to its recent record highs, supported by strong revenue and profit growth driven by its GLP-1 diabetes and obesity portfolio and reflecting a rising market capitalization well above EUR 500 billion as of mid 2025 according to public market data. The Danish pharmaceutical group is listed…